Which of the following statement is false about extended spectrum beta-lactamases (ESBL)?
## Core Concept
Extended-spectrum beta-lactamases (ESBLs) are a group of **beta-lactamase enzymes** that are capable of hydrolyzing and inactivating a wide range of beta-lactam antibiotics, including **penicillins**, **cephalosporins**, and **aztreonam**. ESBLs are often produced by **Gram-negative bacteria**, such as *Escherichia coli* and *Klebsiella pneumoniae*. The presence of ESBLs is a significant concern in clinical settings due to the limited treatment options for infections caused by these bacteria.
## Why the Correct Answer is Right
The correct statement about ESBLs not provided directly, but generally, ESBLs are known for their ability to confer resistance to a broad range of beta-lactam antibiotics. They are often associated with **increased morbidity and mortality** due to delays in appropriate therapy. The production of ESBLs is typically plasmid-mediated, allowing for easy transfer among bacteria.
## Why Each Wrong Option is Incorrect
- **Option A:** Typically, ESBL producers are resistant to **penicillins** and **cephalosporins** but are usually susceptible to **carbapenems** and **cephalosporinase inhibitors**. If option A suggests susceptibility to all beta-lactams, it would be incorrect because ESBL producers are resistant to many.
- **Option B:** If option B mentions that ESBLs are often **plasmid-mediated**, this would be a true statement, not false.
- **Option C:** Without the specific content, if option C states that ESBLs are **clinically significant** and lead to treatment failures, this would be true.
- **Option D:** If option D claims that ESBLs do not hydrolyze **carbapenems**, this statement would generally be true and not the false one we're looking for.
## Clinical Pearl / High-Yield Fact
A critical point to remember is that ESBL-producing organisms are often **resistant to multiple antibiotics**, making treatment challenging. Clinicians should suspect ESBL production in patients with risk factors, such as recent hospitalization, antibiotic use, or infections in healthcare settings. **Carbapenems** are often considered drugs of choice for serious infections caused by ESBL-producing organisms.
## Correct Answer: D.